BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports First Quarter 2019 Financial Results
May 09, 2019 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 09, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
April 01, 2019 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
March 06, 2019 07:00 ET | BeiGene, LTD.
Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration with BeiGene and is...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at Upcoming Investor Conferences
March 04, 2019 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
February 27, 2019 16:15 ET | BeiGene, LTD.
Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China, Feb. 27, 2019 (GLOBE...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
February 22, 2019 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
February 19, 2019 16:30 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
February 13, 2019 16:30 ET | BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, Feb. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day
February 07, 2019 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, Feb. 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
January 14, 2019 16:15 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Jan. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...